Skip to main content
Clinical Trials/NCT01374763
NCT01374763
Completed
Phase 4

A Comparison of PR Oxycodone/Naloxone and PR Oxycodone After Cardiac Surgery

Kati Järvelä1 site in 1 country165 target enrollmentJuly 2011

Overview

Phase
Phase 4
Intervention
Oxycodone
Conditions
Postoperative Pain
Sponsor
Kati Järvelä
Enrollment
165
Locations
1
Primary Endpoint
Duration of opioid-induced bowel dysfunction postoperatively
Status
Completed
Last Updated
14 years ago

Overview

Brief Summary

The aim of the study is to describe the effects of oxycodone/naloxone combination in comparison to oxycodone for the treatment of postoperative pain in patients undergoing cardiac surgery. The hypothesis is that the duration of opioid-induced bowel dysfunction and the need of laxatives will decrease.

Detailed Description

Opioid-induced bowel dysfunction is common in cardiac surgery patients postoperatively. Opioids are needed to treat severe postoperative pain, but they have troublesome side-effects such as nausea, vomiting and bowel dysfunction. These symptoms also limit the use of gastrointestinal tract for nutrition and medication. Combined prolonged-releases oxycodone and naloxone has been shown to provide as effective analgesia as PR oxycodone. Oxycodone/naloxone has also been suggested to improve bowel function without compromising analgesic efficacy. The aim of the study is to describe the effects of oxycodone/naloxone combination in comparison to oxycodone for the treatment of postoperative pain in patients undergoing cardiac surgery. During the first three months of the study, all cardiac surgery patients will be treated with PR oxycodone. During the second part of the study (3 months), all cardiac surgery patients will be treated with PR oxycodone/naloxone. The primary end point is the duration of opioid-induced bowel dysfunction. Need of laxatives will be recorded.

Registry
clinicaltrials.gov
Start Date
July 2011
End Date
December 2011
Last Updated
14 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Kati Järvelä
Responsible Party
Sponsor Investigator
Principal Investigator

Kati Järvelä

MD, PhD

Tampere University Hospital

Eligibility Criteria

Inclusion Criteria

  • Adult cardiac surgery patient

Exclusion Criteria

  • Preoperative continuous use of laxatives
  • Known anatomic or functional gastrointestinal disorder

Arms & Interventions

Oxycodone

Drug: prolonged-release oxycodone

Intervention: Oxycodone

Oxycodone/naloxone

Prolonged-release oxycodone/naloxone

Intervention: Prolonged-release oxycodone/naloxone

Outcomes

Primary Outcomes

Duration of opioid-induced bowel dysfunction postoperatively

Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 5 days

Secondary Outcomes

  • Need of laxatives postoperatively(Participants will be followed for the duration of hospital stay, an expected average of 5 days)

Study Sites (1)

Loading locations...

Similar Trials